Compare iShares MSCI Hong Kong ETF (EWH) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs Regeneron Pharmaceuticals Inc — how do they compare? iShares MSCI Hong Kong ETF trades at $22.06 (market cap $1.16B), while Regeneron Pharmaceuticals Inc trades at $750.8 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 65.6× iShares MSCI Hong Kong ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while iShares MSCI Hong Kong ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Hong Kong ETF for 61 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| EWH | REGN | |
|---|---|---|
Market Cap | $1.16B | $76.14B |
Volume | 3,176,523 | 500,239 |
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $852.03 |
52-Week Low | $20.66 | $557.73 |
Typical Hold Time | 61 Days | 107 Days |
Enterprise Value | — | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH, the iShares MSCI Hong Kong ETF, trades at $22.04, up 2.13% in the last 24 hours. The technical outlook is bearish, with moving averages signaling a downtrend and key support at $21. Recent news highlights volatility in the Hang Seng Index, driven by Federal Reserve decisions and geopolitical tensions. Financial ratios are unavailable in the provided data, limiting fundamental assessment.
The ETF faces headwinds from Hong Kong market weakness and institutional selling, but oversold conditions per RSI may offer tactical opportunities. Risks include ongoing U.S.-China tensions and economic pressures. Investors should weigh exposure to Hong Kong equities against broader market risks.
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
